Patent Overview
A dossier for chronic hepatitis B management, centered on liver-function support, fibrosis-delay context, and combination-therapy positioning.
Indication: Compilation of Materials on Chronic Hepatitis B, Research on Liver Function Support, Communication on Combination Therapy
Principle and Advantage
Hepatitis B Kang is more appropriately defined as a 'combined asset in the long-term management scenario of chronic hepatitis B,' not a substitute for standard antiviral drugs, but rather an entry point for collaboration built around liver function regulation, fibrosis delay, and combination therapy materials.
Scientific Basis: Supporting Vitality and Expelling Pathogenic Factors, Integration of Disease and Syndrome, Integrated Traditional Chinese and Western Medicine Approach to Liver Disease Treatment
- Suitable for packaging as a 'long-term liver disease management information kit' rather than a mere liver-protecting promotional page.
- There is a clear reference relationship with existing standard antiviral regimens, making it easy for partners to quickly understand.
- Can form a series with the liver disease chapter, clinical experience, and subsequent patent assets.
Market Context
Market reference：Therapy context: Long-cycle CHB management; Existing drug baseline: Entecavir / Tenofovir
- The standard treatment pathway for hepatitis B is clear, making it easier for partners to determine the position of this asset within the existing regimen.
- This entry is naturally suitable for being packaged and communicated together with liver disease materials, clinical experience, and combination therapy research.
- The liver disease field has ongoing clinical demand and room for international exchange.
Entecavir
Nucleoside analogue · First-line baseline drug for chronic hepatitis B antiviral treatment.
This asset is more suitable for entering through the lens of combination management and supportive materials, rather than directly substituting first-line antiviral drugs.
Tenofovir
Nucleotide analogue · First-line baseline drug for chronic hepatitis B antiviral treatment.
Can serve as a reference point for partners to understand the current solution landscape.
Peg-IFN-alpha
Immunomodulatory antiviral therapy · An important option in the immunotherapy pathway for chronic hepatitis B.
The package insert places it within the current treatment framework.
Related Books
Research on Pei Zhengxue's Formulation Series
Research on Pei Zhengxue's Series of Formulas and Medicines / Compiled by Zhang Chouchou — Lanzhou: Gansu Science and Te.
Collected Medical Experience of Pei Zhengxue
Collected Medical Experiences of Professor Pei Zhengxue / Compiled and authored by Pei Zhengxue Lanzhou: Gansu Science a.
Cooperation
Suitable as a foundational entry for patent communication, joint research discussions, and bilingual material compilation in the field of liver diseases.
This page is for academic exchange and collaboration reference and does not constitute medical advice, product marketing, or efficacy claims.